Skip to content
Request Info
+61 2 9209 4035
  • Home
  • Solutions
    • Patient Data Analytics
    • Longitudinal Patient Data
    • Data Mapping
    • Pharma Data Analytics & Software
    • Pharma Intelligence & Business Intelligence
    • Data Science
    • Geospatial Mapping
  • Products
    • Platform
    • Market Insights
    • Patient Insights
    • Patient Journey
    • Provider Insights
    • Cohort Builder
    • Patient Profiler
    • Triggers
    • Services
    • Subpopulation Insights
    • RWE Publication
    • Clinical Decision Support
    • Market Assessment
  • About
    • About Prospection
    • Work With Us
  • Articles
  • Contact
  • English
  • Home
  • Solutions
    • Patient Data Analytics
    • Longitudinal Patient Data
    • Data Mapping
    • Pharma Data Analytics & Software
    • Pharma Intelligence & Business Intelligence
    • Data Science
    • Geospatial Mapping
  • Products
    • Platform
    • Market Insights
    • Patient Insights
    • Patient Journey
    • Provider Insights
    • Cohort Builder
    • Patient Profiler
    • Triggers
    • Services
    • Subpopulation Insights
    • RWE Publication
    • Clinical Decision Support
    • Market Assessment
  • About
    • About Prospection
    • Work With Us
  • Articles
  • Contact
  • English

Day: November 2, 2020

Are high coronary risk patients missing out on lipid-lowering drugs in Australia?

To examine whether high coronary risk patients in Australia, where
use of lipid-lowering drugs (LLD) is very high by international standards, are
receiving LLD.

A retrospective review of the persistence of bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population.

Aim: To describe the persistence of biologic disease modifying anti-rheumatic drugs (bDMARDs) in Australian
rheumatoid arthritis (RA) patients, and assess the influence of methotrexate and other conventional DMARD
(cDMARD) concomitant medications, and treatment line on bDMARD persistence and glucocorticoids usage.

Prospection is a leading provider of actionable real world evidence

  • Patient Data Analytics
  • Pharma Intelligence Asia-Pacific
  • Longitudinal Patient Data
  • Pharma Intelligence Japan
  • Data Mapping
  • Pharma Intelligence Singapore
  • Pharma Data Analytics & Software
  • Pharma Intelligence USA
  • Pharma Intelligence & Business Intelligence
  • Pharma Intelligence United Kingdom
  • Data Science
  • Geospatial Mapping
  • Patient Data Analytics
  • Pharma Intelligence Asia-Pacific
  • Longitudinal Patient Data
  • Pharma Intelligence Japan
  • Data Mapping
  • Pharma Intelligence Singapore
  • Pharma Data Analytics & Software
  • Pharma Intelligence USA
  • Pharma Intelligence & Business Intelligence
  • Pharma Intelligence United Kingdom
  • Data Science
  • Geospatial Mapping

Contact Us

  • Level 6 Sydney Central
    477 Pitt Street Haymarket
    NSW 2000 Australia
  • +61 2 9209 4035
  • prospection@prospection.com
Twitter Linkedin

Stay Updated

Register here to stay informed about Prospection

Copyright 2021 Prospection | All Rights Reserved
Privacy Policy
Request Info
+61 2 9209 4035
  • Home
  • Solutions
    • Patient Data Analytics
    • Longitudinal Patient Data
    • Data Mapping
    • Pharma Data Analytics & Software
    • Pharma Intelligence & Business Intelligence
    • Data Science
    • Geospatial Mapping
  • Products
    • Platform
    • Market Insights
    • Patient Insights
    • Patient Journey
    • Provider Insights
    • Cohort Builder
    • Patient Profiler
    • Triggers
    • Services
    • Subpopulation Insights
    • RWE Publication
    • Clinical Decision Support
    • Market Assessment
  • About
    • About Prospection
    • Work With Us
  • Articles
  • Contact
  • English
Request Demo
Login
  • English